Related Experiment Video
Updated: Aug 21, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
FGFR4 suppresses antitumor immunity and cuproptosis by disrupting CYLD-mediated stabilization of STING and FDX1
Hongguang Zhong1, Ruixuan Huang1, Wenyuan Deng2
1Department of Oncology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, 330006, China.
Abstract:
The fibroblast growth factor receptor (FGFR) pathway is frequently dysregulated in cancer and contributes to tumor progression and immune evasion; however, the underlying immunosuppressive mechanisms remain incompletely understood. Here, we identify FGFR4 as a key FGFR family member that suppresses antitumor immunity. Mechanistically, FGFR4 promotes GRB2-dependent phosphorylation and inactivation of the deubiquitinase CYLD, leading to ubiquitin-proteasome-mediated degradation of STING and FDX1. Loss of STING attenuates type I interferon signaling and impairs cytotoxic immune responses, while destabilization of FDX1 diminishes sensitivity to cuproptosis. Inhibition of FGFR4 restores CYLD activity, stabilizes STING and FDX1, and enhances responsiveness to the STING agonist diABZI. Notably, CYLD-dependent stabilization of FDX1 potentiates elesclomol-induced cuproptosis, triggering mitochondrial stress and cytosolic mtDNA release, thereby activating the cGAS-STING pathway and amplifying STING-dependent immune signaling. Combination therapy with lenvatinib and elesclomol synergistically suppressed tumor growth in immunocompetent mouse models. Across patient cohorts, FGFR4-high/STING-low tumors were associated with inferior responses to anti-PD-1-based therapy. Together, these findings establish FGFR4 as a central regulator of antitumor immunity and cuproptosis and highlight combined FGFR4 inhibition and cuproptosis induction as a promising therapeutic strategy.
Insights
Fibroblast growth factor receptor 4 (FGFR4) suppresses antitumor immunity by degrading STING and FDX1. Inhibiting FGFR4 restores immune responses and enhances cancer treatment efficacy, offering a new therapeutic strategy.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Fibroblast growth factor receptor (FGFR) pathway dysregulation is common in cancer, promoting tumor growth and immune evasion.
- The specific mechanisms by which the FGFR pathway suppresses antitumor immunity are not fully understood.
Purpose of the Study:
- To identify key FGFR family members involved in immune suppression.
- To elucidate the molecular mechanisms by which FGFR4 suppresses antitumor immunity.
- To evaluate FGFR4 inhibition and cuproptosis induction as a combined therapeutic strategy.
Main Methods:
- Investigated FGFR4's role in regulating antitumor immunity using molecular assays.
- Examined the impact of FGFR4 on STING and FDX1 stability via GRB2-dependent CYLD inactivation.
- Assessed the efficacy of combined FGFR4 inhibition (lenvatinib) and cuproptosis induction (elesclomol) in preclinical cancer models.
- Correlated FGFR4 and STING expression with patient responses to anti-PD-1 therapy.
Main Results:
- FGFR4 was identified as a suppressor of antitumor immunity.
- FGFR4 inactivation of CYLD leads to STING and FDX1 degradation, impairing interferon signaling and cuproptosis sensitivity.
- FGFR4 inhibition restored CYLD activity, stabilized STING and FDX1, and improved responses to STING agonists.
- Combined lenvatinib and elesclomol synergistically reduced tumor growth in vivo.
- High FGFR4 and low STING expression correlated with poor responses to anti-PD-1 therapy.
Conclusions:
- FGFR4 is a critical regulator of antitumor immunity and cuproptosis.
- Targeting FGFR4 in combination with cuproptosis inducers represents a promising therapeutic approach for cancer.
- FGFR4-mediated immunosuppression presents a potential mechanism for resistance to immunotherapy.
Related Concept Videos
Inhibition of Cdk Activity
Drugs that Destabilize Microtubules
Hedgehog Signaling Pathway
Abnormal Proliferation
The Extrinsic Apoptotic Pathway